Literature DB >> 20541926

Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study.

Julie Bruneau1, Mark Daniel, Yan Kestens, Michal Abrahamowicz, Geng Zang.   

Abstract

BACKGROUND: Cross-sectional associations suggest that body art piercing (BAP) is a risk factor for hepatitis C (HCV) infection among injection drug users. The temporal basis of the relationship has not been established.
METHODS: Associations between HCV seropositivity, HCV incidence, recent BAP and BAP facility availability were evaluated among IDUs followed biannually between 2004 and 2008 in Montreal, Canada. A geographic information system was used to determine the availability of BAP facilities for each participant. Statistical models included individual and neighbourhood covariates. Logistic regression was used for analysis of HCV seropositivity. Cox proportional hazards regression was used for analysis of HCV incidence.
RESULTS: Of 784 IDUs, 73% were seropositive for HCV. In multivariable logistic regression, HCV seropositivity was associated with BAP availability (OR: 1.32 95% confidence interval (CI): 1.1, 1.6) but not recent BAP. Of 145 initially HCV-negative participants, 52 seroconverted to HCV for an incidence of 27.7/100 person-years (95%CI: 20.9, 36.0). Crude hazard ratios (HR) for the association between HCV infection and BAP variables were: recent BAP, HR 0.98 (95%CI: 0.4, 2.7) and BAP facilities availability, HR 1.43 (95%CI: 1.1, 1.9). After accounting for individual and neighbourhood factors, crude associations between HCV infection and recent BAP and BAP facilities availability were: HR recent BAP, 0.96, 95%CI: 0.3, 2.7; and HR BAP facility availability, 1.21, 95%CI: 0.9, 1.7.
CONCLUSION: BAP facility availability is a marker of neighbourhood disadvantage associated with HCV seropositivity. Longitudinal analyses accounting for behaviour risk factors and neighbourhood characteristics do not support a temporal association between BAP acquisition, BAP facility availability, and HCV infection among IDUs.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541926     DOI: 10.1016/j.drugpo.2010.05.001

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  6 in total

Review 1.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity.

Authors:  Jason Grebely; Gregory J Dore
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 3.  Transmission of hepatitis C virus infection through tattooing and piercing: a critical review.

Authors:  Rania A Tohme; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

Review 4.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196

6.  Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.

Authors:  Jason Grebely; Viviane Dias Lima; Brandon D L Marshall; M-J Milloy; Kora DeBeck; Julio Montaner; Annick Simo; Mel Krajden; Gregory J Dore; Thomas Kerr; Evan Wood
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.